HOME >> MEDICINE >> NEWS
Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy

Late-breaking presentation shows multilineage blood cell growth with excellent safety in chemotherapy patients

Maret Pharmaceuticals, Inc. today reported positive Phase I/II clinical results that demonstrate the potential of MARstem™ as a multilineage hematopoietic therapy (multiple blood cell stimulant) to treat or prevent pancytopenia (a reduction in different types of blood cells) following chemotherapy in breast cancer patients. The study was selected as a late breaking abstract at the 11th National Cancer Institute - European Organization for Research and Treatment of Cancer - American Association for Cancer Research (NCI-EORTC-AACR) Symposium on New Drugs in Cancer Therapy.

The study was designed to evaluate safety, optimal dose and proof-of-principle efficacy of MARstem in adjuvant breast cancer patients. The results show that MARstem reduced the frequency of grade 2-4 thrombocytopenia (decrease in the number of blood platelets), grade 2-4 anemia (deficiency in red blood cells), and grade 3-4 lymphopenia (reduction in the number of lymphocytes) as compared to controls.

"These early clinical results suggest that MARstem may effective in improving or reducing the debilitating side effects of cancer treatment," said Terry Winters, Ph.D., Chairman and Chief Executive Officer of Maret Pharmaceuticals. MARstem has a clear therapeutic benefit as a multilineage hematopoietic factor as compared to traditional hematopoietic stimulants, which selectively increase only a single blood cell line. The trials outcome is promising, as the safety of MARstem has been established and the preliminary efficacy results are encouraging.

The studys results suggest that MARstem exhibits an excellent safety profile. There were no dose-limiting toxicities in the patients treated with MARstem. Specifically, there were no adverse cardiovascular or hematologic effects. The overall occurrence of side effects was lower in MARstem pa
'"/>

Contact: Heather Rosoff
hrosoff@fkhealth.com
617-761-6770
Feinstein Kean Healthcare
9-Nov-2000


Page: 1 2

Related medicine news :

1. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
2. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
3. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
4. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
5. Pharmaceuticals and personal care products
6. Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement
7. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis
8. Beyond Pharmaceuticals: Business And Academic Leaders Forecast The Future Of "Combinatorial Chemistry"
9. ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting
10. American Academy of Neurology presents 57th Annual Meeting in Miami Beach
11. Hard choices: Pitt researcher presents findings on when to accept organ transplants

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/14/2019)... Mass. (PRWEB) , ... February 14, 2019 , ... ... raising money for the specific purpose of preparing its two disruptive spine portfolio companies, ... acquisition in the next 3-5 years. , The spine industry is consolidating evidenced ...
(Date:2/13/2019)... MIAMI (PRWEB) , ... February 14, 2019 , ... At ... 20,000 global entrepreneurs leapt to their feet and cheered as it was announced that ... Over the course of the last few years, the company has optimized its revolutionary ...
(Date:2/13/2019)... INDIANAPOLIS (PRWEB) , ... February 13, 2019 , ... ... playgrounds and in high school locker rooms. Unfortunately, bullies also frequent hospital units, ... colleagues and peers. , In this fully updated, second edition of What ...
(Date:2/13/2019)... ... February 13, 2019 , ... ... SXSW ,’ four days of programming occurring at SXSW 2019 in Austin, ... organizations, industry and philanthropy to innovate, collaborate and activate initiatives aimed at ...
(Date:2/13/2019)... ... February 13, 2019 , ... ... at the company’s annual member conference, Elevate 2019 at the Gaylord Rockies Resort ... and members to explore potential partnerships driving improved quality of patient care, reduced ...
Breaking Medicine News(10 mins):
(Date:2/13/2019)... ... February 13, 2019 , ... Researchers from the Icahn School of ... Institute on Aging, part of the National Institutes of Health (NIH), for a five-year ... , The program’s goals are to establish follicle-stimulating hormone (FSH), an important part of ...
(Date:2/13/2019)... ... February 13, 2019 , ... According to the National ... has a BMI of 26.5, which is considered overweight (the healthy range is 18.4-24.9). ... the 1980’s into the new millennium, and now news outlets are regularly reporting it ...
(Date:2/13/2019)... , ... February 13, 2019 , ... The Medicus Firm ... Staff Physician Recruiters (ASPR). “The Medicus Firm has been a vocal and enthusiastic ... Industry stewardship and support of educational programs are part of our DNA and becoming ...
Breaking Medicine Technology:
Cached News: